TED Pharmacotherapy: Corticosteroids, Teprotumumab, and Emerging Biologics – Global Forecast

Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Thyroid Eye Disease Treatment Drug – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Thyroid Eye Disease Treatment Drug market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Thyroid Eye Disease Treatment Drug was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.

Thyroid eye disease is an eye disease caused by autoimmune hyperthyroidism. The role of thyroid eye disease treatment drugs is mainly to relieve symptoms and prevent the progression of diseases such as proptosis by adjusting thyroid function, suppressing immune response, and reducing inflammation. These medications are often used together when treating thyroid eye disease, and the specific treatment plan will be based on the patient’s symptoms and severity of the condition. During treatment, doctors usually adjust the dosage and type of drugs based on the patient’s response and changes in condition. Overall, these drugs work by modulating the immune system and thyroid function to reduce symptoms and control disease progression.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975287/thyroid-eye-disease-treatment-drug

1. Core Market Definition & Critical Pain Points

Thyroid eye disease (TED) – also known as Graves’ orbitopathy – is a debilitating autoimmune condition causing proptosis (eye bulging), diplopia (double vision), periorbital edema, and in severe cases, compressive optic neuropathy and vision loss. Thyroid eye disease treatment drugs target the underlying IGF-1R and TSHR pathways, reduce orbital inflammation, and prevent irreversible proptosis. For endocrinologists, ophthalmologists, and patients, core needs include rapid symptom relief, prevention of disease progression (especially optic nerve compromise), reduction of surgical orbital decompression rates, and long-term safety.

2. Market Size & Recent 6-Month Trajectory (Q4 2025 – Q2 2026)

According to QYResearch’s latest tracking (integrating company annual reports, securities filings, and ophthalmology prescribing data), the global Thyroid Eye Disease Treatment Drug market demonstrated accelerated growth through late 2025 and into 2026:

2025 estimated value: US$ million (full report)
2032 projected value: US$ million
Implied CAGR (2026-2032): %

Observed six-month trends:

Immunosuppressants segment (especially anti-IGF-1R monoclonal antibodies) grew fastest (≈25-30%), driven by teprotumumab (Tepezza®) adoption as first-line for moderate-to-severe active TED
Glucocorticoids (IV methylprednisolone, oral prednisone) remain standard for acute inflammation but declining in share due to side effects (weight gain, hyperglycemia, osteoporosis)
Antithyroid drugs (methimazole, propylthiouracil) – essential for managing hyperthyroidism but do not directly treat orbital disease
Geographic hotspots: North America (highest biologic uptake), Europe (strong glucocorticoid use, growing teprotumumab adoption), Asia-Pacific (emerging market, cost constraints limit biologics)

3. Key Industry Development Characteristics (2021–2026)

3.1 Type Segmentation: Antithyroid Drugs, Glucocorticoids, Immunosuppressants

Drug Class	Mechanism	Key Agents	Primary TED Indication	Limitations
Antithyroid Drugs	Inhibit thyroid peroxidase (methimazole, PTU)	Methimazole, Propylthiouracil	Manage hyperthyroidism (indirect benefit for TED)	No direct orbital effect; PTU hepatotoxicity risk
Glucocorticoids	Broad anti-inflammatory (NF-κB inhibition)	IV methylprednisolone (pulse), oral prednisone	Active moderate-severe TED (first-line before 2020)	Weight gain, hyperglycemia, osteoporosis, Cushing’s syndrome
Immunosuppressants	Anti-IGF-1R (teprotumumab), calcineurin inhibitors, rituximab	Teprotumumab (Tepezza®), Mycophenolate, Rituximab	Active TED (proptosis reduction), steroid-refractory cases	High cost (teprotumumab ~$300,000/course), infusion reactions
Others (selenium, pentoxifylline)	Antioxidant, anti-fibrotic	Sodium selenite, Pentoxifylline	Mild TED, adjunctive	Weak evidence, not disease-modifying

Key trend: Teprotumumab (anti-IGF-1R monoclonal antibody) has revolutionized TED treatment. Phase II/III trials (Horizon, OPTIC) showed proptosis reduction (mean -2.4mm vs. placebo -0.4mm) and CAS improvement. Now guideline-endorsed first-line for active moderate-severe TED.

3.2 Treatment Layering: Active vs. Inactive TED; Mild vs. Moderate-Severe

Exclusive industry observation: Thyroid eye disease treatment drugs differ fundamentally based on disease phase:

Active TED (inflammatory phase, CAS ≥4): Target inflammation – IV glucocorticoids or teprotumumab. Goal: prevent progression to sight-threatening complications.
Inactive TED (fibrotic phase, CAS <4): No active inflammation; drugs ineffective. Surgical rehabilitation (orbital decompression, strabismus surgery) becomes primary.

CAS (Clinical Activity Score) : 7-point scale (pain, redness, swelling, function). Score ≥4 indicates active disease requiring immunosuppression.

Market implication: Teprotumumab approved only for active TED (not inactive). This limits eligible population to ~40% of TED patients at any given time (disease activity fluctuates).

4. Competitive Landscape & Leading Players (QYResearch 2026 Database)

Based on verified annual reports, securities disclosures, and clinical trial data:

Novartis – No dedicated TED drug but provides systemic immunosuppressants (mycophenolate off-label) and anti-thyroid drugs (via generics arm Sandoz).
Sanofi – Marketed teprotumumab (Tepezza®) acquired via Horizon Therapeutics acquisition (2023). Holds dominant (~80%) share of branded TED biologic market.
AbbVie – No specific TED drug; provides adalimumab (Humira®) studied off-label for TED (limited efficacy).
Roche – Tocilizumab (Actemra®) anti-IL-6 receptor studied in Phase II for TED (NCT03922399) – results mixed; not approved.
Allergan (AbbVie) – No TED-specific drugs; provides medical devices for orbital surgery.

Strategic insight: The TED drug market is highly concentrated with Sanofi (via Tepezza®) dominating the biologic space. Generic glucocorticoids (methylprednisolone, prednisone) remain widely used but are low-margin. New entrants include Viridian Therapeutics (VRDN-001, anti-IGF-1R antibody, Phase III) and Immunovant (batoclimab, anti-FcRn, Phase II) – but not yet marketed.

5. End-Use Application Deep Dive & User Cases

5.1 Hospital Segment (~70-75% of market value)

Primary settings: Academic medical centers, tertiary care hospitals with neuro-ophthalmology and endocrinology collaboration.

Treatment protocols:

Mild TED (CAS 1-3, no diplopia) : Selenium 200μg daily + supportive care (artificial tears, smoking cessation, euthyroidism maintenance).
Moderate-severe active TED (CAS ≥4, proptosis) : First-line – teprotumumab (10mg/kg IV every 3 weeks for 8 infusions) OR IV methylprednisolone (4.5g cumulative over 12 weeks).
Sight-threatening TED (optic neuropathy) : High-dose IV methylprednisolone (1g daily for 3 days) + urgent orbital decompression if no response.

Typical user case (Q1 2026) : A 52-year-old female with active TED (CAS 6, proptosis 25mm, diplopia). Endocrinologist initiated teprotumumab (Sanofi) at a hospital infusion center. After 4 infusions (week 12): CAS reduced to 2, proptosis decreased by 3mm, diplopia resolved. Infusion-related side effects: mild muscle spasms (managed with calcium/magnesium). Completed full 8-infusion course. Insurance prior authorization required (approx. 2 weeks).

5.2 Clinic Segment (~20-25% of market value)

Primary settings: Endocrinology outpatient clinics, ophthalmology private practices (mild TED, long-term monitoring).

Decision criteria: Lower acuity patients (mild TED), steroid courses (oral prednisone for flares), monitoring euthyroidism.

User case (Q2 2026) : An Australian endocrine clinic treated a 34-year-old male with mild TED (CAS 3, proptosis 21mm) with oral selenium and methimazole. At 6 months: CAS improved to 2, no proptosis progression. No steroids or biologics required. Patient counseled on smoking cessation (smoker: 1 pack/day).

5.3 Other Segment (~5%)

Includes long-term care, rehabilitation facilities, and clinical trial sites (investigational agents).

6. Technical Challenges & Industry Response

Critical unresolved issue #1: Teprotumumab cost and access – At ~$300,000 per 8-infusion course, many insurers require prior authorization, step therapy (failed steroids), or restrict to specialist centers.

Industry responses:

Patient assistance programs (Sanipro Helps, Horizon Cares) – income-based copay assistance
International reference pricing – Canadian and European prices lower (negotiated via public systems)
Biosimilar threat: Viridian’s VRDN-001 could enter market 2027-2028 at reduced price

Critical unresolved issue #2: Hearing adverse events – Post-marketing reports of sensorineural hearing loss with teprotumumab (≈10% incidence in OPTIC trial, higher in real-world).

Mitigation:

Baseline audiometry and monitoring every 2-3 infusions
Discontinue if hearing loss confirmed (some reversible on停药; others permanent)
Alternative agent (IV steroids) for high-risk patients

FDA action (2025): Added hearing loss warning to Tepezza® label; required REMS program for audiometry monitoring.

Critical unresolved issue #3: Lack of oral agents for active TED – All active disease treatments require IV infusion (teprotumumab, methylprednisolone) – inconvenient and resource-intensive.

Emerging pipeline: Viridian’s VRDN-001 subcutaneous formulation (weekly injection) in Phase III – could improve access.

7. Policy Drivers & Regional Dynamics

Guideline updates:
- European Thyroid Association (ETA) 2025 Guidelines: Recommends teprotumumab as first-line for moderate-severe active TED (upgraded from second-line after steroids in 2021 guidelines).
- American Thyroid Association (ATA) : Same recommendation (2024 update) – but insurance coverage variable.
Reimbursement:
- US Medicare: Covers teprotumumab under Part B (medical benefit) with prior authorization; patient copay 20% (~$60,000) unless supplemental coverage.
- UK NHS: NICE approved teprotumumab (2024) for active TED with proptosis ≥3mm; requires specialist center administration.
- China: Not yet approved (NMPA review ongoing, expected 2027); current treatment: IV steroids and orbital surgery.

8. Forecast Summary & Strategic Recommendations

With a projected CAGR of % (2026-2032) , the global Thyroid Eye Disease Treatment Drug market offers clear strategic imperatives:

For manufacturers: Develop subcutaneous anti-IGF-1R antibodies to improve patient convenience. Conduct head-to-head trials vs. teprotumumab to demonstrate non-inferiority with better safety (hearing). Explore combination therapy (anti-IGF-1R + anti-TSHR) for synergy.
For endocrinologists and ophthalmologists: Use CAS scoring to identify active disease early; initiate teprotumumab within 6 months of active TED for best proptosis reduction. Monitor hearing at baseline and every 2 infusions.
For hospitals/infusion centers: Establish multidisciplinary TED clinics (endocrinology, ophthalmology, otolaryngology) to coordinate care. Obtain prior authorization for teprotumumab proactively (2-4 weeks lead time).

*To access the complete report with 10-year forecasts, competitive market share matrix, type analysis, and 25+ drug profiles:*